Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

OncoVerity, Inc.

Home Clinical Trial Sponsors and OrganizationsOncoVerity, Inc.

OncoVerity, Inc.

ACTIVE

12635 E Montview Blvd, Aurora, 科罗拉多州, United StatesHoldingEstablished: 2022-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

11

7 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2022

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

8

72.7%

Phase 2

3

27.3%

Trial Status Distribution

Active, not recruiting

7

63.6%

Completed

3

27.3%

Recruiting

1

9.1%

Clinical Trials

Trials sponsored by this organization (11)

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

Active, not recruiting

Jul 2024140 participants

A Clinical Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia who are not Candidates for Intensive Chemotherapy

Active, not recruiting

Jul 202465 participants

An Open-label, Multicenter, Phase 1b Study of OV-1001 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia

Active, not recruiting

Jul 202450 participants

A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy

Active, not recruiting

May 2024177 participants

A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment

Mar 20206 participants

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia

Active, not recruiting

Dec 201961 participants

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy

Active, not recruiting

Jul 2019103 participants

A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

Dec 201638 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials11
Approvals
News

Back to Organizations